OBJECTIVE: To investigate the expression of CD147 in prostate cancer and discuss its diagnostic value in prostate cancer. METHODS: The method of immunohistochemical SP was employed to detect the expression of CD147 in 101 cases of prostate cancer, 90 cases of benign prostatic hyperplasia, 36 cases of normal prostate and 15 cases of embryonic prostate by so as to evaluate its clinical significance in the histological classification and prognosis of prostate cancer. RESULTS: The CD147 expression was positively expressed in 67/101 (66.3%) of prostate cancer, 21/90 (23.3%) of benign prostatic hypertrophy, 2/36 (5.6%) of normal prostate and 0/15 (0.0) of embryonic prostate respectively. A positive expression of CD147 was dramatically associated with TNM stage (P < 0.001), the depth of prostatic capsule invasion (P = 0.002) and histological grade (P = 0.006). CONCLUSIONS: The detection of CD147 is helpful to raise the early diagnosis rate of prostate cancer. It will become a tumor marker of reflecting the malignant degree and predicting the prognosis of prostate cancer.
OBJECTIVE: To investigate the expression of CD147 in prostate cancer and discuss its diagnostic value in prostate cancer. METHODS: The method of immunohistochemical SP was employed to detect the expression of CD147 in 101 cases of prostate cancer, 90 cases of benign prostatic hyperplasia, 36 cases of normal prostate and 15 cases of embryonic prostate by so as to evaluate its clinical significance in the histological classification and prognosis of prostate cancer. RESULTS: The CD147 expression was positively expressed in 67/101 (66.3%) of prostate cancer, 21/90 (23.3%) of benign prostatic hypertrophy, 2/36 (5.6%) of normal prostate and 0/15 (0.0) of embryonic prostate respectively. A positive expression of CD147 was dramatically associated with TNM stage (P < 0.001), the depth of prostatic capsule invasion (P = 0.002) and histological grade (P = 0.006). CONCLUSIONS: The detection of CD147 is helpful to raise the early diagnosis rate of prostate cancer. It will become a tumor marker of reflecting the malignant degree and predicting the prognosis of prostate cancer.
Authors: Yun Ye; Su-Liang Li; Yao Wang; Yang Yao; Juan Wang; Yue-Yun Ma; Xiao-Ke Hao Journal: Drug Des Devel Ther Date: 2016-08-01 Impact factor: 4.162